Table 3.
Weight loss, pharmacotherapy and surgical treatment in 113 patients with IIH
| Weight loss | n | 86 |
| Weight loss ≥ 6% from weight at diagnosis | n (%) | 49 (57.0) |
| Change of weight absolute (kg) | Median (IQR; AR) | −7 (−15–−1; −75–43) |
| Change of weight percentage (%) | Median (IQR; AR) | −6.8 (−14.9–−1.3; −58.6–40.2) |
| IIH specific medication | n | 113 |
| Acetazolamide | n (%) | 112 (99.1) |
| Maximum acetazolamide dosage (mg) | Median (IQR; AR) | 750 (500–1000; 250–2000) |
| Topiramate | n (%) | 15 (13.3) |
| Maximum topiramate dosage (mg) | Median (IQR; AR) | 62.5 (50–75; 25–200) |
| Furosemide | n (%) | 12 (10.6) |
| Maximum furosemide dosage (mg) | Median (IQR; AR) | 35.0 (20–40; 20–160) |
| Combination treatment | n (%) | 23 (20.4) |
| Therapeutic lumbar puncture | n | 113 |
| Entire study perioda | n (%) | 63 (55.8) |
| Cumulative numbera | Median (IQR; AR) | 1 (0–4; 0–26) |
| Follow-up (> 4 weeks after diagnosis) | n (%) | 27 (26.2) |
| Cumulative number | Median (IQR; AR) | 0 (0–1; 0–23) |
| Surgery | n | 113 |
| Ventricular peritoneal/atrial shunt | n (%) | 14 (12.4) |
| Shunt revision | n (%) | 3 (21.4) |
| Bariatric surgery | n (%) | 1 (0.9) |
IQR interquartile range, AR absolute range
anot including initial diagnostic lumbar puncture